SG10201701524XA - Boronate ester compounds and pharmaceutical compositions thereof - Google Patents

Boronate ester compounds and pharmaceutical compositions thereof

Info

Publication number
SG10201701524XA
SG10201701524XA SG10201701524XA SG10201701524XA SG10201701524XA SG 10201701524X A SG10201701524X A SG 10201701524XA SG 10201701524X A SG10201701524X A SG 10201701524XA SG 10201701524X A SG10201701524X A SG 10201701524XA SG 10201701524X A SG10201701524X A SG 10201701524XA
Authority
SG
Singapore
Prior art keywords
pharmaceutical compositions
ester compounds
boronate ester
boronate
compounds
Prior art date
Application number
SG10201701524XA
Inventor
Eric L Elliott
Abu J Ferdous
Michael J Kaufman
Sonja A Komar
Debra L Mazaik
Quentin J Mccubbin
Phoung M Nguyen
Vaithianathan Palaniappan
Raymond D Skwierczynski
Nobel T Truong
Csanad M Varga
Peter N Zawaneh
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41061278&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201701524X(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of SG10201701524XA publication Critical patent/SG10201701524XA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/04—Esters of boric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/81—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/82—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/83—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/05—Cyclic compounds having at least one ring containing boron but no carbon in the ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
SG10201701524XA 2008-06-17 2009-06-16 Boronate ester compounds and pharmaceutical compositions thereof SG10201701524XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13224408P 2008-06-17 2008-06-17
US21149909P 2009-03-31 2009-03-31

Publications (1)

Publication Number Publication Date
SG10201701524XA true SG10201701524XA (en) 2017-04-27

Family

ID=41061278

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201701524XA SG10201701524XA (en) 2008-06-17 2009-06-16 Boronate ester compounds and pharmaceutical compositions thereof
SG2013069851A SG194349A1 (en) 2008-06-17 2009-06-16 Boronate ester compounds and pharmaceutical compositions thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG2013069851A SG194349A1 (en) 2008-06-17 2009-06-16 Boronate ester compounds and pharmaceutical compositions thereof

Country Status (38)

Country Link
US (17) US20090325903A1 (en)
EP (6) EP2730580A1 (en)
JP (9) JP5566380B2 (en)
KR (5) KR101691093B1 (en)
CN (10) CN103435638A (en)
AR (1) AR072162A1 (en)
AU (1) AU2009260778B2 (en)
BR (4) BR122014008750A2 (en)
CA (2) CA2727862C (en)
CL (1) CL2010001475A1 (en)
CO (1) CO6321289A2 (en)
CR (3) CR11850A (en)
CY (1) CY1116435T1 (en)
DK (2) DK2730581T3 (en)
DO (1) DOP2010000384A (en)
EA (4) EA030685B1 (en)
EC (2) ECSP11010763A (en)
ES (2) ES2585114T3 (en)
GE (2) GEP201706703B (en)
HK (9) HK1198252A1 (en)
HR (1) HRP20150592T1 (en)
IL (3) IL210056B (en)
MA (1) MA32471B1 (en)
MX (4) MX2010013642A (en)
MY (2) MY155592A (en)
NO (1) NO2017016I1 (en)
NZ (4) NZ624123A (en)
PE (5) PE20141064A1 (en)
PH (3) PH12015501191A1 (en)
PL (1) PL2318419T3 (en)
PT (2) PT2318419E (en)
RS (1) RS54020B1 (en)
SG (2) SG10201701524XA (en)
SI (1) SI2318419T1 (en)
TW (3) TWI498333B (en)
UA (1) UA115131C2 (en)
WO (1) WO2009154737A1 (en)
ZA (4) ZA201009177B (en)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2623113T (en) 2005-11-09 2017-07-14 Onyx Therapeutics Inc Compound for enzyme inhibition
JP5226679B2 (en) 2006-06-19 2013-07-03 プロテオリックス， インコーポレイテッド Compounds for enzyme inhibition
EA024437B1 (en) 2007-10-04 2016-09-30 Оникс Терапьютикс, Инк. Synthesis of amino acid keto-epoxides
EA030685B1 (en) 2008-06-17 2018-09-28 Милленниум Фармасьютикалз, Инк. Process for the preparation of a boronate ester compound
KR101023994B1 (en) 2008-08-28 2011-03-28 한국생산기술연구원 Connector for Digital Band, Receptacle and Connector Assembly
AR075090A1 (en) 2008-09-29 2011-03-09 Millennium Pharm Inc ACID DERIVATIVES 1-AMINO-2-CYCLLOBUTILETILBORONICO PROTEOSOMA INHIBITORS, USEFUL AS ANTI-BANKER AGENTS, AND PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THEM.
BRPI0919668A2 (en) 2008-10-21 2018-05-29 Onyx Therapeutics, Inc. peptide epoxy ketone combination therapy
TWI504598B (en) 2009-03-20 2015-10-21 Onyx Therapeutics Inc Crystalline tripeptide epoxy ketone protease inhibitors
WO2011060179A1 (en) 2009-11-13 2011-05-19 Onyx Therapeutics, Inc Use of peptide epoxyketones for metastasis suppression
EP2542238B1 (en) 2010-03-01 2015-08-12 Onyx Therapeutics, Inc. Compounds for immunoproteasome inhibition
CN106008570A (en) * 2010-03-31 2016-10-12 米伦纽姆医药公司 Derivatives of 1-amino-2-cyclopropylethylboronic acid
CA2813003A1 (en) * 2010-10-05 2012-04-12 Fresenius Kabi Usa, Llc Bortezomib formulations stabilised with boric acid
CN102784114B (en) * 2011-05-14 2016-03-02 山东新时代药业有限公司 A kind of bortezomib freeze-dried powder and preparation method thereof
JP5944986B2 (en) 2011-06-22 2016-07-05 セファロン、インク． Proteasome inhibitors and processes for their preparation, purification, and use
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013071142A1 (en) 2011-11-11 2013-05-16 Millennium Pharmaceuticals, Inc. Biomarkers of response to proteasome inhibitors
EP2776586B1 (en) 2011-11-11 2018-03-07 Millennium Pharmaceuticals, Inc. Biomarkers of response to proteasome inhibitors
US9732101B2 (en) 2012-01-18 2017-08-15 Wisconsin Alumni Research Foundation Bioreversible boronates for delivery of molecules into cells
US9234048B2 (en) 2012-01-18 2016-01-12 Wisconsin Alumni Research Foundation Boronate-mediated delivery of molecules into cells
EP2812338A4 (en) 2012-01-24 2015-09-23 Millennium Pharm Inc Method of treatment of nasopharyngeal caner
CN104204797B (en) 2012-01-24 2017-05-31 米伦纽姆医药公司 The method for the treatment of cancer
WO2013128419A2 (en) * 2012-03-02 2013-09-06 Dr. Reddy's Laboratories Limited Pharmaceutical compositions comprising boronic acid compounds
CA2784240C (en) 2012-03-27 2014-07-08 Innopharma, Inc. Stable bortezomib formulations
US9309283B2 (en) 2012-07-09 2016-04-12 Onyx Therapeutics, Inc. Prodrugs of peptide epoxy ketone protease inhibitors
ITMI20121394A1 (en) * 2012-08-06 2014-02-07 Chemi Spa ESTERS OF BORTEZOMIB AND THEIR FORMULATIONS
EP3008212A4 (en) * 2013-06-10 2017-05-24 Millennium Pharmaceuticals, Inc. Methods of treatment of cancer
JP6165986B2 (en) * 2013-08-23 2017-07-19 シントン・ビー．ブイ．Ｓｙｎｔｈｏｎ Ｂ．Ｖ． Pharmaceutical composition comprising bortezomib
WO2015051067A1 (en) 2013-10-03 2015-04-09 Millennium Pharmaceuticals, Inc. Method for the prophylaxis or treatment of systemic lupus erythematosus and/or lupus nephritis
WO2015117136A1 (en) * 2014-02-03 2015-08-06 Ohio State Innovation Foundation Boronic acid esters and pharmaceutical formulations thereof
JP2015200016A (en) * 2014-03-31 2015-11-12 富士フイルム株式会社 Photoelectrode for water decomposition and water decomposition apparatus
SG11201609259VA (en) * 2014-05-20 2016-12-29 Millennium Pharm Inc Boron-containing proteasome inhibitors for use after primary cancer therapy
US10301273B2 (en) 2014-08-07 2019-05-28 Mayo Foundation For Medical Education And Research Compounds and methods for treating cancer
WO2016069955A1 (en) * 2014-10-29 2016-05-06 Wisconsin Alumni Research Foundation Boronic acid inhibitors of hiv protease
EP3031811A1 (en) 2014-12-09 2016-06-15 Teva Pharmaceuticals Ltd. Malic acid esters of bortezomib
MA41505A (en) * 2015-02-11 2017-12-19 Millennium Pharm Inc NEW CRYSTALLINE FORM OF A PROTEASOME INHIBITOR
MA41555A (en) * 2015-02-17 2017-12-26 Millennium Pharm Inc POLYTHERAPY FOR CANCER TREATMENT
CZ2015233A3 (en) 2015-04-03 2016-10-12 Zentiva, K.S. Process for preparing ixazomib citrate
CZ2015253A3 (en) 2015-04-15 2016-10-26 Zentiva, K.S. Novel forms of ixazomib citrate
WO2016205790A2 (en) * 2015-06-19 2016-12-22 Hanlin Scientific, Inc. Chiral specific boron-containing compounds and their use in treating cancer or amyloidosis
CN108135916B (en) * 2015-06-19 2022-01-28 北京科辉智药生物科技有限责任公司 Chiral specific boron-containing compounds and their use in the treatment of cancer or amyloidosis
EP3120836A1 (en) 2015-07-22 2017-01-25 Stada Arzneimittel Ag Ready-to-use solution of bortezomib
EP3120837A1 (en) 2015-07-22 2017-01-25 Stada Arzneimittel Ag Ready-to-use solution of bortezomib
WO2017046815A1 (en) 2015-09-16 2017-03-23 Mylan Laboratories Limited Polymorphs of ixazomib citrate and processes for the preparation thereof
CN106608883A (en) * 2015-10-21 2017-05-03 北京大学 Synthetic method of proteasome inhibitor MLN9708
WO2017079572A1 (en) 2015-11-04 2017-05-11 Millennium Pharmaceuticals, Inc. Methods for the identification, evaluation and treatment of patients having multiple myeloma
CN106986884A (en) * 2016-01-20 2017-07-28 成都贝斯凯瑞生物科技有限公司 A kind of efficient high-purity boron-containing compound preparation method
CN105622658B (en) * 2016-03-18 2018-06-19 中国药科大学 Non-peptide albuminoid enzyme body inhibitor, its pharmaceutical composition, preparation method and application
WO2017163190A1 (en) * 2016-03-23 2017-09-28 Dr. Reddy’S Laboratories Limited Amorphous ixazomib citrate and solid dispersion thereof
CN107224569A (en) * 2016-03-26 2017-10-03 复旦大学 Water-soluble Pharmaceutical composition of a kind of bortezomib and its production and use
CZ2016204A3 (en) 2016-04-08 2017-11-01 Zentiva, K.S. Formulation of ixazomib citrate of form 3
WO2017222819A2 (en) * 2016-06-21 2017-12-28 Teva Pharmaceuticals International Gmbh Solid state forms of ixazomib citrate
EP3476850A4 (en) * 2016-07-25 2019-06-19 Shenzhen Targetrx, Inc. Substituted boric acid compound, pharmaceutical composition comprising same, and application thereof
WO2018027022A1 (en) * 2016-08-04 2018-02-08 Millennium Pharmaceuticals, Inc. Combination of proteasome inhibitors and anti-cd30 antibodies
WO2018133661A1 (en) * 2017-01-23 2018-07-26 成都奥璟生物科技有限公司 Novel boric acid derivative and pharmaceutical composition using same
EP3589659A4 (en) 2017-02-28 2021-03-24 Mayo Foundation for Medical Education and Research Compounds and methods for treating cancer
WO2018158697A1 (en) 2017-03-03 2018-09-07 Fresenius Kabi Oncology Limited A process for the preparation of ixazomib citrate
WO2018173071A1 (en) * 2017-03-20 2018-09-27 Msn Laboratories Private Limited, R&D Center Novel crystalline forms of ixazomib citrate and its process for preparation thereof
CN106916177B (en) * 2017-03-23 2019-04-23 南京陵瑞医药科技有限公司 A kind of deuterated dipeptide boronic acid or its ester type compound and its synthetic method and purposes
CN108794516A (en) * 2017-04-26 2018-11-13 上海时莱生物技术有限公司 Boric acid and boric acid ester compound and its preparation method and application
CN108794520B (en) * 2017-05-02 2020-07-24 北京大学 Synthesis method of boric acid citrate compounds including Eszolomide
WO2019020099A1 (en) * 2017-07-28 2019-01-31 成都地奥九泓制药厂 Borate compound, and synthesis method therefor and uses thereof
EP3672977B1 (en) 2017-08-24 2022-06-22 Merck Patent GmbH Boronic acid derivatives
EP3672978B1 (en) 2017-08-25 2021-10-06 Synthon B.V. Process for making ixazomib and its intermediates
WO2019043544A1 (en) * 2017-09-02 2019-03-07 Sun Pharmaceutical Industries Limited Process for the preparation of ixazomib citrate
WO2019053611A1 (en) 2017-09-14 2019-03-21 Glaxosmithkline Intellectual Property Development Limited Combination treatment for cancer
CN113603713A (en) * 2017-12-05 2021-11-05 深圳市塔吉瑞生物医药有限公司 Preparation method and crystal form of substituted boric acid ester compound
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone
US10118937B1 (en) 2018-01-03 2018-11-06 Scinopharm Taiwan, Ltd. Process for preparing ixazomib citrate and intermediates therefor
CN110041353A (en) * 2018-01-16 2019-07-23 成都译山生物科技有限公司 A kind of new boric acid salicylate analog derivative and its pharmaceutical composition
CA3091805A1 (en) 2018-03-05 2019-09-12 Arcus Biosciences, Inc. Arginase inhibitors
US11243207B2 (en) 2018-03-29 2022-02-08 Mayo Foundation For Medical Education And Research Assessing and treating cancer
CN110540547A (en) * 2018-05-28 2019-12-06 秦艳茹 Synthesis and application of peptide borate compound
CA3107377A1 (en) 2018-07-26 2020-01-30 Merck Patent Gmbh Boronic acid derivatives
MX2021001089A (en) * 2018-08-02 2021-05-12 Chia Tai Tianqing Pharmaceutical Group Co Ltd Borate of azetidine derivative.
CN110903310B (en) * 2018-09-14 2022-11-22 成都奥璟生物科技有限公司 Boric acid ester medicine and application thereof
CN110357787A (en) * 2019-08-02 2019-10-22 苏州艾和医药科技有限公司 Yi Shazuo meter synthesising process research
WO2023220655A1 (en) 2022-05-11 2023-11-16 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
WO2023220641A2 (en) 2022-05-11 2023-11-16 Juno Therapeutics, Inc. Methods and uses related to t cell therapy and production of same
WO2023232830A1 (en) 2022-06-02 2023-12-07 Merck Patent Gmbh Boronic acid adducts
WO2024006337A1 (en) 2022-06-30 2024-01-04 Principia Biopharma Inc. Cyclic boronic esters and their uses
WO2024097905A1 (en) 2022-11-02 2024-05-10 Celgene Corporation Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy
CN117964650B (en) * 2024-03-28 2024-06-07 成都硕德药业有限公司 Preparation method of citric acid Sha Zuomi

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US449082A (en) * 1891-03-24 milbeadt
US2160413A (en) 1935-04-16 1939-05-30 Schering Ag Polyiodo derivatives of acylamino acids and their salts and a method of making the same
NZ203706A (en) 1982-04-22 1986-03-14 Squibb & Sons Inc Occlusive multi-layer wound dressing and hydrocolloidal granules for wound treatment
US4499082A (en) 1983-12-05 1985-02-12 E. I. Du Pont De Nemours And Company α-Aminoboronic acid peptides
JPS6233170A (en) 1985-08-07 1987-02-13 Tokuyama Soda Co Ltd Cyclic polyether compound
JPH0813759B2 (en) 1986-09-01 1996-02-14 富士写真フイルム株式会社 Method for producing alkoxybenzene derivative
JP2512303B2 (en) 1987-03-20 1996-07-03 呉羽化学工業株式会社 Phenylhydrazone derivative of 2-oxazoline-4,5-dione
US5187157A (en) 1987-06-05 1993-02-16 Du Pont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
US5250720A (en) 1987-06-05 1993-10-05 The Dupont Merck Pharmaceutical Company Intermediates for preparing peptide boronic acid inhibitors of trypsin-like proteases
US5242904A (en) 1987-06-05 1993-09-07 The Dupont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
EP0315574A3 (en) 1987-11-05 1990-08-22 Hoechst Aktiengesellschaft Renin inhibitors
US5159060A (en) * 1988-05-27 1992-10-27 Mayo Foundation For Medical Education And Research Cytotoxic boronic acid peptide analogs
US5106948A (en) 1988-05-27 1992-04-21 Mao Foundation For Medical Education And Research Cytotoxic boronic acid peptide analogs
DE3827340A1 (en) 1988-08-12 1990-02-15 Hoechst Ag USE OF (ALPHA) -AMINOBORONIC ACID DERIVATIVES FOR THE PROPHYLAXIS AND TREATMENT OF VIRUS DISEASES
MX9206628A (en) 1991-11-22 1993-05-01 Boehringer Ingelheim Pharma PROLINABORONATE ESTER AND METHOD FOR ITS PREPARATION.
ES2098484T3 (en) 1992-08-14 1997-05-01 Procter & Gamble LIQUID DETERGENTS CONTAINING AN ALPHA-AMINO-BORONIC ACID.
US5442100A (en) * 1992-08-14 1995-08-15 The Procter & Gamble Company β-aminoalkyl and β-N-peptidylaminoalkyl boronic acids
US5492900A (en) * 1993-09-10 1996-02-20 Neutron Technology Corporation Method for enhancing the solubility of the boron delivery drug, boronophenylalanine (BPA)
US5935944A (en) * 1993-09-10 1999-08-10 Neutron Technology Corporation Formulation for I.V. administration of the boron delivery drug, boronophenylalanine (BPA)
US6060462A (en) * 1993-10-20 2000-05-09 Dupont Pharmaceuticals Company Electrophilic peptide analogs as inhibitors of trypsin-like enzymes
FR2712602B1 (en) 1993-11-18 1996-02-09 Centre Nat Rech Scient Recombinant viruses, preparation and use in gene therapy.
US5574017A (en) * 1994-07-05 1996-11-12 Gutheil; William G. Antibacterial agents
US6083903A (en) * 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US5614649A (en) * 1994-11-14 1997-03-25 Cephalon, Inc. Multicatalytic protease inhibitors
JP3403009B2 (en) * 1996-07-12 2003-05-06 キヤノン株式会社 Liquid discharge method involving displacement of movable member and bubble growth, liquid discharge head used for the discharge method, head cartridge, and liquid discharge apparatus using these
US5834487A (en) 1996-09-24 1998-11-10 Cv Therapeutics Inhibition of 26S and 20S proteasome by indanones
JP2001511814A (en) 1997-02-15 2001-08-14 プロスクリプト・インコーポレイテッド Treatment of infarction through inhibition of NF-κB
AU9580098A (en) 1997-09-25 1999-04-12 Millennium Pharmaceuticals, Inc. Proteasome inhibitors, ubiquitin pathway inhibitors or agents that interfere with the activation of nf-(k)b via the ubiquitin proteasome pathway to treat inflammatory and autoimmune diseases
CA2314259A1 (en) 1997-12-16 1999-06-24 Robert Siman Multicatalytic protease inhibitors for use as anti-tumor agents
US6075150A (en) 1998-01-26 2000-06-13 Cv Therapeutics, Inc. α-ketoamide inhibitors of 20S proteasome
WO2000024392A1 (en) 1998-10-26 2000-05-04 Sumitomo Pharmaceuticals Company, Limited β-AMYLOID FORMATION INHIBITORS
US6169076B1 (en) * 1999-03-31 2001-01-02 Glcosyn Pharmaceuticals, Inc. P-Boronophenylalanine complexes with fructose and related carbohydrates and polyols
US6121149A (en) * 1999-04-22 2000-09-19 Advanced Micro Devices, Inc. Optimized trench/via profile for damascene filling
KR100307027B1 (en) 1999-06-17 2001-11-01 서평원 Apparatus For Liquid Crystal Display And Apparatus For Display in Mobile Telecommunication Terminal of Using Thereof
WO2001002424A2 (en) 1999-07-07 2001-01-11 Du Pont Pharmaceuticals Company Peptide boronic acid inhibitors of hepatitis c virus protease
SE0100714D0 (en) 2000-07-13 2001-02-28 Ap Biotech Ab Reaction vessel and method for distributing fluid in such a vessel
US6846806B2 (en) 2000-10-23 2005-01-25 Bristol-Myers Squibb Company Peptide inhibitors of Hepatitis C virus NS3 protein
JP2002145848A (en) * 2000-11-10 2002-05-22 Kyorin Pharmaceut Co Ltd Alkenylamino acid derivative and method for manufacturing the same
EP1217000A1 (en) * 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
EP2251344B2 (en) * 2001-01-25 2024-04-24 THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Formulation of boronic acid compounds
DE60209227T2 (en) 2001-05-30 2006-08-17 Novartis Ag 2 - ((N- (2-AMINO-3- (HETEROARYL- OR -ARYL) PROPIONYL) AMINOACYL) AMINO) -ALKYLBORONIC ACID DERIVATIVES
DE10131283A1 (en) 2001-06-28 2003-01-09 Philips Corp Intellectual Pty Phased array antenna
JPWO2003033506A1 (en) 2001-10-12 2005-02-03 杏林製薬株式会社 Aminoboranoic acid derivatives and proteasome inhibitors containing the same
WO2003033507A1 (en) 2001-10-12 2003-04-24 Kyorin Pharmaceutical Co., Ltd. Benzylmalonic acid derivatives and proteasome inhibitors contaiing the same
EP1463719A2 (en) 2002-01-08 2004-10-06 Eisai Co., Ltd Eponemycin and epoxomicin analogs and uses thereof
AU2003223930A1 (en) 2002-06-14 2003-12-31 Novo Nordisk A/S Pharmaceutical use of boronic acids and esters thereof
US20060084592A1 (en) 2002-09-09 2006-04-20 Trigen Limited Peptide boronic acid inhibitors
JP2006511593A (en) 2002-09-09 2006-04-06 トライジェン・リミテッド Boronate and its use in the treatment of thrombosis
TW200418791A (en) 2003-01-23 2004-10-01 Bristol Myers Squibb Co Pharmaceutical compositions for inhibiting proteasome
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
MY162518A (en) * 2003-08-14 2017-06-15 Cephalon Inc Proteasome inhibitors and methods of using the same
US7223745B2 (en) 2003-08-14 2007-05-29 Cephalon, Inc. Proteasome inhibitors and methods of using the same
US7576206B2 (en) * 2003-08-14 2009-08-18 Cephalon, Inc. Proteasome inhibitors and methods of using the same
GB0405267D0 (en) 2004-03-09 2004-04-21 Trigen Ltd Compounds
PT2377869E (en) 2004-03-30 2014-04-15 Millennium Pharm Inc Synthesis of bortezomib
PL2030981T3 (en) 2004-05-10 2014-12-31 Onyx Therapeutics Inc Compounds for proteasome enzyme inhibition
WO2006008660A2 (en) 2004-07-20 2006-01-26 Affinium Pharmaceuticals, Inc. Streptococcus pneumoniae enoyl- (acyl-carrier-protein) reductase (fabk)
TW200618820A (en) 2004-11-05 2006-06-16 Alza Corp Liposome formulations of boronic acid compounds
US7468383B2 (en) 2005-02-11 2008-12-23 Cephalon, Inc. Proteasome inhibitors and methods of using the same
CN101120006A (en) * 2005-02-11 2008-02-06 赛福伦公司 Proteasome inhibitors and methods of using the same
BRPI0609861A2 (en) 2005-04-29 2010-05-11 Kosan Biosciences Inc use of 17-aag or 17-ag or a prodrug of both in combination with a proteasome inhibitor in the preparation of pharmaceutical formulations for treating multiple myeloma
US7998997B2 (en) 2005-07-05 2011-08-16 Trustees Of Tufts College Inhibitors of fibroblast activation protein alpha
WO2007067444A1 (en) * 2005-12-08 2007-06-14 Millennium Pharmaceuticals, Inc. Bicyclic compounds with kinase inhibitory activity
JP2009524681A (en) 2006-01-27 2009-07-02 フェノミックス コーポレーション Hepatitis C virus serine protease inhibitor and uses therefor
CN101415691B (en) 2006-02-03 2011-12-14 大正制药株式会社 Triazole derivative
CL2007002499A1 (en) * 2006-08-30 2008-03-14 Phenomix Corp SALES CITRATE AND TARTRATE OF COMPOUNDS DERIVED FROM PIRROLIDINILAMINOACETILPIRROLIDINBORONICO ACID, DPP-IV INHIBITORS; PREPARATION METHOD; SOLID FORM; PHARMACEUTICAL COMBINATION, USEFUL FOR THE TREATMENT OF DIABETES.
WO2009006473A2 (en) 2007-07-05 2009-01-08 Trustees Of Tufts College Pro-soft polypeptide proteasome inhibitors, and methods of use thereof
US7442830B1 (en) * 2007-08-06 2008-10-28 Millenium Pharmaceuticals, Inc. Proteasome inhibitors
DK2178888T3 (en) 2007-08-06 2012-10-01 Millennium Pharm Inc proteasome inhibitors
ITMI20072397A1 (en) 2007-12-20 2009-06-21 Gambro Lundia Ab MEDICAL EQUIPMENT FOR EXTRA-REPAIR TREATMENT
EA030685B1 (en) * 2008-06-17 2018-09-28 Милленниум Фармасьютикалз, Инк. Process for the preparation of a boronate ester compound
AR075090A1 (en) 2008-09-29 2011-03-09 Millennium Pharm Inc ACID DERIVATIVES 1-AMINO-2-CYCLLOBUTILETILBORONICO PROTEOSOMA INHIBITORS, USEFUL AS ANTI-BANKER AGENTS, AND PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THEM.
CN106008570A (en) 2010-03-31 2016-10-12 米伦纽姆医药公司 Derivatives of 1-amino-2-cyclopropylethylboronic acid
PT2702706E (en) 2011-04-29 2015-04-08 Ericsson Telefon Ab L M Decentralised control of interference reduction in a wireless communication system
JP5724951B2 (en) 2012-06-11 2015-05-27 日立金属株式会社 Network management device
JP6357023B2 (en) 2014-06-06 2018-07-11 任天堂株式会社 Information processing program, information processing apparatus, information processing apparatus control method, and information processing system

Also Published As

Publication number Publication date
EA201170036A1 (en) 2011-06-30
JP2020055829A (en) 2020-04-09
EP2730580A1 (en) 2014-05-14
TWI543985B (en) 2016-08-01
US20130165390A1 (en) 2013-06-27
BRPI0915300B1 (en) 2020-06-23
TW201433569A (en) 2014-09-01
JP6010066B2 (en) 2016-10-19
EP2318419B2 (en) 2024-10-30
CN107266480A (en) 2017-10-20
IL234286A (en) 2017-03-30
NZ624123A (en) 2015-11-27
JP5926319B2 (en) 2016-05-25
US20220009948A1 (en) 2022-01-13
CA2727862A1 (en) 2009-12-23
ECSP14010763A (en) 2014-07-31
BRPI0915300C1 (en) 2021-05-25
KR101690571B1 (en) 2016-12-28
DK2730581T3 (en) 2016-08-15
JP5566380B2 (en) 2014-08-06
IL210056B (en) 2018-04-30
CR20160015A (en) 2016-03-09
PT2730581T (en) 2016-08-17
CN102066386A (en) 2011-05-18
US20140018301A9 (en) 2014-01-16
AU2009260778A1 (en) 2009-12-23
CA2921946A1 (en) 2009-12-23
JP2023158150A (en) 2023-10-26
JP2014169316A (en) 2014-09-18
US20190152997A1 (en) 2019-05-23
EA201500430A1 (en) 2015-11-30
MX2010013642A (en) 2010-12-21
BRPI0915300A2 (en) 2015-10-27
AR072162A1 (en) 2010-08-11
US20160031913A1 (en) 2016-02-04
EP3536693A1 (en) 2019-09-11
JP2014144981A (en) 2014-08-14
TWI542351B (en) 2016-07-21
US20200002361A1 (en) 2020-01-02
EP2733147A1 (en) 2014-05-21
ZA201109368B (en) 2013-10-30
HK1199260A1 (en) 2015-06-26
CY1116435T1 (en) 2017-02-08
PH12015501191B1 (en) 2016-01-11
US20180002350A1 (en) 2018-01-04
IL210056A0 (en) 2011-02-28
HRP20150592T1 (en) 2015-07-03
DK2318419T3 (en) 2015-06-29
JP6110813B2 (en) 2017-04-05
US20210198289A1 (en) 2021-07-01
CO6321289A2 (en) 2011-09-20
ECSP11010763A (en) 2011-02-28
GEP201706703B (en) 2017-07-25
PL2318419T3 (en) 2015-08-31
KR20140107483A (en) 2014-09-04
US20140343314A1 (en) 2014-11-20
MX349769B (en) 2017-08-11
EP2730579A1 (en) 2014-05-14
AU2009260778B2 (en) 2014-08-28
EP2318419A1 (en) 2011-05-11
US20200392164A1 (en) 2020-12-17
NZ624121A (en) 2015-11-27
GEP20135847B (en) 2013-06-10
MX358222B (en) 2018-08-10
JP2021165288A (en) 2021-10-14
CR11850A (en) 2011-03-14
EA201500432A1 (en) 2015-11-30
BR122014008750A2 (en) 2015-11-03
JP2014169317A (en) 2014-09-18
KR101704694B1 (en) 2017-02-08
MA32471B1 (en) 2011-07-03
JP2014196310A (en) 2014-10-16
BR122014008754A2 (en) 2015-11-03
US8859504B2 (en) 2014-10-14
US10604538B2 (en) 2020-03-31
US20200181176A1 (en) 2020-06-11
TWI498333B (en) 2015-09-01
KR101741142B1 (en) 2017-05-29
EA027346B1 (en) 2017-07-31
ZA201009177B (en) 2012-03-28
KR101691093B1 (en) 2016-12-29
MY155592A (en) 2015-11-13
PH12015501191A1 (en) 2016-01-11
BR122014008753A2 (en) 2015-12-29
CL2010001475A1 (en) 2011-03-11
EA201500431A1 (en) 2015-11-30
CN103467565A (en) 2013-12-25
ES2541467T3 (en) 2015-07-20
CN107253966A (en) 2017-10-17
CN107266482A (en) 2017-10-20
PH12015501193A1 (en) 2016-01-11
KR20140107482A (en) 2014-09-04
TW201433317A (en) 2014-09-01
US10526351B2 (en) 2020-01-07
CA2727862C (en) 2016-04-19
KR101860743B1 (en) 2018-05-24
BRPI0915300B8 (en) 2020-07-07
NO2017016I1 (en) 2017-05-04
US20190048028A1 (en) 2019-02-14
CN107253975A (en) 2017-10-17
EA030685B1 (en) 2018-09-28
CR20160014A (en) 2016-02-08
CA2921946C (en) 2019-01-08
ES2585114T3 (en) 2016-10-03
NZ624122A (en) 2015-11-27
ZA201304728B (en) 2016-01-27
DOP2010000384A (en) 2011-01-15
PT2318419E (en) 2015-08-25
CN103450241A (en) 2013-12-18
US20090325903A1 (en) 2009-12-31
CN103497232A (en) 2014-01-08
HK1244810A1 (en) 2018-08-17
PE20141065A1 (en) 2014-09-05
PH12015501192A1 (en) 2016-01-11
PE20141076A1 (en) 2014-09-05
HK1244811A1 (en) 2018-08-17
US20180208609A1 (en) 2018-07-26
HK1198253A1 (en) 2015-03-20
WO2009154737A1 (en) 2009-12-23
HK1198252A1 (en) 2015-03-20
SI2318419T1 (en) 2015-07-31
US9175018B2 (en) 2015-11-03
HK1157786A1 (en) 2012-07-06
JP2017214396A (en) 2017-12-07
US11485746B2 (en) 2022-11-01
US20150307523A9 (en) 2015-10-29
US20230265111A1 (en) 2023-08-24
PE20100256A1 (en) 2010-04-14
PE20141078A1 (en) 2014-09-05
IL234285B (en) 2018-04-30
NZ603236A (en) 2014-05-30
HK1198254A1 (en) 2015-03-20
CN103497210A (en) 2014-01-08
RS54020B1 (en) 2015-10-30
UA115131C2 (en) 2017-09-25
PE20141064A1 (en) 2014-09-05
US20200247829A1 (en) 2020-08-06
TW201002727A (en) 2010-01-16
MY171021A (en) 2019-09-23
US9175017B2 (en) 2015-11-03
KR20170068599A (en) 2017-06-19
KR20140094663A (en) 2014-07-30
HK1244827A1 (en) 2018-08-17
EP2730581A1 (en) 2014-05-14
EP2730581B1 (en) 2016-04-27
CN103435638A (en) 2013-12-11
PH12015501192B1 (en) 2016-01-11
KR20110043599A (en) 2011-04-27
HK1244809A1 (en) 2018-08-17
JP2011524903A (en) 2011-09-08
ZA201504133B (en) 2016-11-30
MX340186B (en) 2016-06-29
US20140349966A1 (en) 2014-11-27
EP2318419B1 (en) 2015-04-08
SG194349A1 (en) 2013-11-29
US20190263839A1 (en) 2019-08-29

Similar Documents

Publication Publication Date Title
HK1244811A1 (en) Boronate ester compounds and pharmaceutical compositions thereof
EP2240022A4 (en) Pharmaceutical compositions
GB0814695D0 (en) Pharmaceutical compositions
EP2373681A4 (en) Pharmaceutical compositions
PL2323623T3 (en) Pharmaceutical compositions
EP2268278A4 (en) Pharmaceutical composition
HK1156844A1 (en) Pharmaceutical composition 271 271
IL206487A0 (en) Pharmaceutical compositions
GB0917359D0 (en) Pharmaceutical composition
GB0902648D0 (en) Pharmaceutical compounds and compositions
GB0908317D0 (en) Pharmaceutical compounds and compositions
GB0817969D0 (en) Pharmaceutical composition
GB0800659D0 (en) Pharmaceutical Compositions
SI2271321T1 (en) Pharmaceutical composition 271
GB0908069D0 (en) Pharmaceutical compounds and compositions
GB0902651D0 (en) Pharmaceutical compounds and compositions
GB0903945D0 (en) Pharmaceutical compounds and compositions
GB0919055D0 (en) Pharmaceutical compounds and compositions
GB0802024D0 (en) Pharmaceutical compositions
GB0806156D0 (en) Pharmaceutical compositions
GB0806283D0 (en) Pharmaceutical compositions
EP2308842A4 (en) Pharmaceutical compositions
GB0817566D0 (en) Pharmaceutical composition
GB0817974D0 (en) Pharmaceutical composition